Insulet (NASDAQ:PODD) Price Target Lowered to $150.00 at UBS Group

Insulet (NASDAQ:PODD) Price Target Lowered to $150.00 at UBS Group

UBS Group lowered their price target on Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a research note on Thursday.

Insulet slightly lowers 2026 sales growth outlook despite Q2 beats

Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However,  it lowered that outlook by 1% at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth greater than 30% from the previous year, compared to the previous suggestion of greate…